MYCOPHENOLATE MOFETIL VS CYCLOPHOSPHAMIDE IN SCLERODERMA ASSOCIATED INTERSTITIAL LUNG DISEASE(ILD) - SINGLE CENTER OBSERVATIONAL STUDY

被引：0
|
作者：
Bavaliya, M. [1 ]
Padmanabha, S. [1 ]
机构：
[1] Amrita Inst Med Scienece, Kochi, Kerala, India
来源：
INTERNAL MEDICINE JOURNAL | 2015年 / 45卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
ARP85
引用
收藏
页码：34 / 34
页数：1
相关论文
共 50 条
  • [1] CYCLOPHOSPHAMIDE VS MYCOPHENOLATE MOFETIL IN SCLERODERMA INTERSTITIAL LUNG DISEASE (SSC-ILD) AS INDUCTION THERAPY: A SINGLE CENTER, RETROSPECTIVE ANALYSIS
    Bavliya, M. K.
    Shenoy, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 1115 - 1115
  • [2] MYCOPHENOLATE MOFETIL (MMF) IN SCLERODERMA (SSc) ASSOCIATED INTERSTITIAL LUNG DISEASE (ILD) AND SKIN DISEASE - THE AUSTRALIAN EXPERIENCE
    Jayaweera, S.
    Sahhar, J.
    Englert, H.
    Proudman, S.
    Hill, C.
    Youssef, P.
    INTERNAL MEDICINE JOURNAL, 2011, 41 : 11 - 11
  • [3] Mycophenolate mofetil for interstitial lung disease in scleroderma
    Plastiras, S. C.
    Vlachoyiannopoulos, P. G.
    Tzelepis, G. E.
    RHEUMATOLOGY, 2006, 45 (12) : 1572 - 1572
  • [4] MYCOPHENOLATE MOFETIL VERSUS ORAL CYCLOPHOSPHAMIDE IN SCLERODERMA-RELATED INTERSTITIAL LUNG DISEASE: SCLERODERMA LUNG STUDY II
    Khanna, D.
    Roth, M.
    Clements, P.
    Furst, D.
    Tseng, C. -H.
    Elashoff, R.
    Volkmann, E.
    Kafaja, S.
    Goldin, J.
    Tashkin, D.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 531 - 531
  • [5] Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis
    Shenoy, Padmanabha D.
    Bavaliya, Manish
    Sashidharan, Sujith
    Nalianda, Kaveri
    Sreenath, Sreelakshmi
    ARTHRITIS RESEARCH & THERAPY, 2016, 18
  • [6] Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis
    Padmanabha D. Shenoy
    Manish Bavaliya
    Sujith Sashidharan
    Kaveri Nalianda
    Sreelakshmi Sreenath
    Arthritis Research & Therapy, 18
  • [7] Effect Of Mycophenolate Mofetil On Scleroderma-Associated Interstitial Lung Disease
    Baqir, M.
    Makol, A.
    Osborn, T. G.
    Bartholmai, B.
    Ryu, J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [8] Scleroderma Lung Study Ii: Comparison Of Therapy With Mycophenolate Mofetil Versus Oral Cyclophosphamide In Patients With Symptomatic Scleroderma Interstitial Lung Disease
    Tashkin, D. P.
    Roth, M. D.
    Furst, D. E.
    Clements, P.
    Khanna, D.
    Volkmann, E.
    Kalafa, S.
    Goldin, J.
    Kim, G. H. J.
    Arriola, E.
    Tseng, C. -H.
    Elashoff, R. E.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [9] Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease
    Zamora, Ana C.
    Wolters, Paul J.
    Collard, Harold R.
    Connolly, M. Kari
    Elicker, Brett M.
    Webb, W. Richard
    King, Talmadge E., Jr.
    Golden, Jeffrey A.
    RESPIRATORY MEDICINE, 2008, 102 (01) : 150 - 155
  • [10] Efficacy and Safety of Mycophenolate (MMF) Vs Oral Cyclophosphamide (CYC) for Treatment of Scleroderma-Interstitial Lung Disease (Ssc-ILD): Results of Scleroderma Lung Study II
    Tashkin, Donald
    Roth, Michael
    Clements, Philip
    Furst, Daniel
    Khanna, Dinesh
    Goldin, Jonathan
    Kleerup, Eric
    Arriola, Edgar
    Tseng, Chi-Hong
    Elashoff, Robert
    CHEST, 2015, 148 (04)
12345